en · de · es · fr · pt
melanotan-2-notes.peptides6823.com › Guide › Melanotan Ii Background And Mechanism — Research Overview

Melanotan Ii Background And Mechanism — Research Overview

By Editorial Desk · published 2025-07-01 · last reviewed 2025-07-27 · Guide

A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-07-27. Anything still debated is marked as such rather than presented as settled.

Melanotan II Background and Mechanism

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Regulatory Status and Analytical Detection

Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.

The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideMelanocortin receptor agonist
Molecular formulaC50H69N15O9Neutral form, mass near 1024.2 g/mol
Primary targetsMC1R, MC3R, MC4R, MC5RBinding is non-selective across subtypes
Related compoundsAlpha-MSH, melanotan I, afamelanotideStructurally or functionally related peptides
Common abbreviationsMT-II, MT-2Naming in the literature is not uniform

Origins and Research Status

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Related pages on this site

Quality Control and Analytical Practice

Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.

Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.

Melanotan-2 Identity And Regulatory Status

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Background from the literature

=== EC 1.11.1 Peroxidases === EC 1.11.1.1: NADH peroxidase EC 1.11.1.2: NADPH peroxidase EC 1.11.1.3: fatty-acid peroxidase EC 1.11.1.4: Now EC 1.13.11.11 EC 1.13.11.11 tryptophan 2,3-dioxygenase EC 1.11.1.5: cytochrome-c peroxidase EC 1.11.1.6: catalase EC 1.11.1.7: peroxidase EC 1.11.1.8: iodide peroxidase EC 1.11.1.9: glutathione peroxidase EC 1.11.1.10: chloride peroxidase EC 1.11.1.11: L-ascorbate peroxidase EC 1.11.1.12: phospholipid-hydroperoxide glutathione peroxidase EC 1.11.1.13: manganese peroxidase EC 1.11.1.14: lignin peroxidase EC 1.11.1.15: Now described by EC 1.11.1.24, thioredoxin-dependent peroxiredoxin; EC 1.11.1.25, glutaredoxin-dependent peroxiredoxin; EC 1.11.1.26, NADH-dependent peroxiredoxin; EC 1.11.1.27, glutathione-dependent peroxiredoxin; EC 1.11.1.28, lipoyl-dependent peroxiredoxin; and EC 1.11.1.29, mycoredoxin-dependent peroxiredoxin EC 1.11.1.16: versatile peroxidase EC 1.11.1.17: glutathione amide-dependent peroxidase EC 1.11.1.18: bromide peroxidase EC 1.11.1.19: dye decolorizing peroxidase EC 1.11.1.20: prostamide/prostaglandin F2α synthase EC 1.11.1.21: catalase-peroxidase EC 1.11.1.22: hydroperoxy fatty acid reductase EC 1.11.1.23: (S)-2-hydroxypropylphosphonic acid epoxidase EC 1.11.1.24: thioredoxin-dependent peroxiredoxin EC 1.11.1.25: glutaredoxin-dependent peroxiredoxin EC 1.11.1.26: NADH-dependent peroxiredoxin EC 1.11.1.27: glutathione-dependent peroxiredoxin EC 1.11.1.28: lipoyl-dependent peroxiredoxin EC 1.11.1.29: mycoredoxin-dependent peroxiredoxin

Craniocervical instability (CCI) is a medical condition characterized by excessive movement of the vertebra at the atlanto-occipital joint and the atlanto-axial joint located between the skull and the top two vertebra, known as C1 and C2. The condition can cause neural injury and compression of nearby structures, including the brain stem, spinal cord, vagus nerve, and vertebral artery, resulting in a constellation of symptoms. Craniocervical instability is more common in people with a connective tissue disease, including Ehlers–Danlos syndromes, osteogenesis imperfecta, and rheumatoid arthritis. It is frequently co-morbid with atlanto-axial joint instability, Chiari malformation, or tethered spinal cord syndrome. The condition can be brought on by physical trauma, including whiplash, laxity of the ligaments surrounding the joint, or other damage to the surrounding connective tissue.

=== Afterhyperpolarization === The depolarized voltage opens additional voltage-dependent potassium channels, and some of these do not close right away when the membrane returns to its normal resting voltage. In addition, further potassium channels open in response to the influx of calcium ions during the action potential. The intracellular concentration of potassium ions is transiently unusually low, making the membrane voltage Vm even closer to the potassium equilibrium voltage EK. The membrane potential goes below the resting membrane potential. Hence, there is an undershoot or hyperpolarization, termed an afterhyperpolarization, that persists until the membrane potassium permeability returns to its usual value, restoring the membrane potential to the resting state.

Sources: en.wikipedia.org

Further detail

== Adverse effects == Although the absorption of betamethasone dipropionate is small, when used for prolonged periods of time (periods exceeding two weeks), or across a large surface area (total use greater than 50 grams per week), it can have adverse effects. One such effect is the ability of the corticosteroid to suppress the hypothalamic–pituitary–adrenal axis. This can lead to a depression in the release of adrenal hormones such as cortisol and adrenocorticotropic hormone, or ACTH. Symptoms of HPA axis suppression are often subtle and variable, but can often be detected using simple blood or urine tests such at ACTH stimulation test or urinary free cortisol. Those at increased risk for HPA axis suppression are those who are more likely to absorb more of the steroid through the skin. These groups include:

In 2017, there were 39,773 deaths in the United States as a result of gunshot wounds. Of these 60% were suicides, 37% were homicides, 1.4% were by law enforcement, 1.2% were accidents, and 0.9% were from an unknown cause. This is up from 37,200 deaths in 2016 due to a gunshot wound (10.6 per 100,000). With respect to those that pertain to interpersonal violence, it had the 31st highest rate in the world with 3.85 deaths per 100,000 people in 2016. The majority of all homicides and suicides are firearm-related, and the majority of firearm-related deaths are the result of murder and suicide. When sorted by GDP, however, the United States has a much higher violent gun death rate compared to other developed countries, with over 10 times the number of firearms assault deaths than the next four highest GDP countries combined. Gunshot violence is the third most costly cause of injury and the fourth most expensive form of hospitalization in the United States.

On September 26, 1983, Stanislav Petrov received convincing indications of an American first strike launch against the Soviet Union, but positively identified the warning as a false alarm. Though it is unclear what role Petrov's actions played in preventing a nuclear war during this incident, he has been honored by the United Nations for his actions.

Sources: en.wikipedia.org

Background from the literature

=== Biology and medicine === Abductor digiti minimi muscle of hand Adrenomedullin, a vasodilator peptide hormone Acinar-to-ductal metaplasia, a condition affecting pancreatic cells (see Acinar cell § Acinar-to-ductal metaplasia)

Children with the FOLR1 mutation are born healthy. Symptoms typically appear at about 5 to 24 months of age. The symptoms get worse with time. Without treatment there may be poor muscle tone, trouble with coordination, trouble talking, and seizures. In addition, signs of psychomotor retardation, sleep disturbances, cerebellar ataxia, and delayed development of head growth can occur. At around age three, visual disturbances can develop, and sensorineural hearing loss can occur at around age six. In cerebral folate deficiency, the brain does not receive a proper supply of 5-MTHF and fails to properly grow. There may be visible loss of white matter in the brain (leukodystrophy) upon imaging.

== Structure == The chordae tendineae connect the atrioventricular valves (tricuspid and mitral), to the papillary muscles within the ventricles. Multiple chordae tendineae attach to each leaflet or cusp of the valves. Chordae tendineae contain elastin in a delicate structure notably at their periphery.

In continuum mechanics, viscosity is a property of a fluid that quantifies the resistance force acting on fluids when there is relative motion between fluid parcels. This resistance force is caused by the stress in fluid parcels, which ideally is directly proportional to the strain rate (the time derivative of strain) that arises when fluid parcels are in relative motion, and the relative speed between the boundary between adjacent fluid parcels is zero. In liquids, viscosity arises from cohesive molecular forces, while in gases it results from molecular collisions. Except for the case of superfluidity, there is no fluid with zero viscosity, and thus all fluid flows involve viscous effects to some degree. For liquids, it corresponds to the informal concept of thickness; for example, syrup has a higher viscosity than water. Viscosity is defined scientifically as a force multiplied by a time divided by an area. Thus its SI units are newton-seconds per metre squared, or pascal-seconds. For instance, when a viscous fluid is forced through a tube, it flows more quickly near the tube's center line than near its walls. Some stress (such as a pressure difference between the two ends of the tube) is needed to sustain the flow. This is because a force is required to overcome the friction between the layers of the fluid which are in relative motion. For a tube with a constant rate of flow, the strength of the compensating force is proportional to the fluid's viscosity. In general, viscosity depends on a fluid's state, such as its temperature, pressure, and rate of deformation.

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is melanotan II?

It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.

Does it require ultraviolet light to work?

Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.

Why is receptor selectivity discussed so often?

Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.

Is melanotan II legal to buy?

Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.

Network